National Institutes of Health to Grant Exclusive Patent License for Anti-TAG72 Monoclonal Antibodies

Summary

The National Institutes of Health is seeking to grant an exclusive patent license to practice certain inventions related to anti-TAG72 monoclonal antibodies, which are being explored as a tumor-specific imaging agent and drug delivery therapeutic, as outlined in several patents and patent applications filed between 1990 and 2006.